Senores Pharmaceuticals

Senores Pharmaceuticals

643.35
-25.60
(-3.83%)
Market Cap
2,962.90 Cr
EPS
16.12
PE Ratio
43.83
Dividend Yield
0.00 %
Industry
Healthcare
52 Week High
705.00
52 Week Low
435.25
PB Ratio
3.77
Debt to Equity
1.28
Add Ratio
hide

Investment Returns

In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Analyst Rating
- By Refinitiv from1 analysts
BUY
Analysts have suggested that investors can buy this stock
Buy
Buy+100.00 %
+100.00 %
Hold
Hold0.0 %
0.0 %
Sell
Sell0.0 %
0.0 %

Company News

View All News
Caret
neutral
Havix has completed a USFDA inspection and received 3 observations related to minor issues. The company has 15 days to respond to these observations from the regulatory authority.
positive
Senores Pharmaceuticals Reports 72% Revenue Growth in Q1FY26 with Strong Performance Across Segments5 days ago
Senores Pharmaceuticals Limited reported strong quarterly results with total income rising 72% year-over-year to Rs. 138 crores. EBITDA increased 60% to Rs. 34.2 crores while profit after tax surged 95% to Rs. 21.2 crores. The company achieved positive operating cash flow of Rs. 11 crores and increased its stake in subsidiary Havix to 73% from 66.6% in December 2024. Regulated Markets contributed 65% of total revenue at Rs. 90.1 crores, up 69% year-over-year. The Branded Generics business showed exceptional growth of 358% to Rs. 8.2 crores. The company received ANDA approval for 4 products, commercialized 2 products, and launched 5 new products during the quarter. Senores operates across 40+ countries with 308 approved products in emerging markets and 70 approved ANDA products in regulated markets. The company maintains manufacturing facilities in Atlanta, US and Ahmedabad, India, serving both regulated and emerging markets.
positive
Senores Pharmaceuticals Limited announced its quarterly results for the quarter ended June 30, 2025, showing consolidated total income of Rs 138 crores, representing 72% year-on-year growth. The company reported EBITDA of Rs 34 crores (60% Y-o-Y growth) and profit after tax of Rs 21 crores (95% Y-o-Y growth). Regulated Markets revenue reached Rs 90 crores with 69% Y-o-Y growth, while Emerging Markets revenue stood at Rs 29 crores with 32% Y-o-Y growth. The company launched 2 ANDA products and received approval for 4 products during the quarter. Additionally, the board appointed Mr. Jignesh Shashikant Desai as President-Finance and categorized him as Senior Management Personnel effective July 23, 2025. The company reported positive operating cash flow of Rs 11 crores for the quarter.
Competitors
LTP
Market Cap (₹ Cr.)
P/E Ratio
Revenue (₹ Cr.)
YoY Revenue Growth %
Net Profit (₹ Cr.)
YoY Profit Growth %
RSI
1,702.20
#1 4,08,414.80
35.66
#1 54,729.00
12.06
#1 10,980
-18.99
55.97
6,584.00
1,74,784.50
79.73
9,712.00
0.89
2,191
23.05
40.37
1,572.00
1,26,971.70
23.53
28,409.50
7.12
5,291
9.88
70.77
3,622.90
1,22,615.40
60.75
11,539.40
6.99
1,911
19.91
72.46
1,287.40
1,07,442.70
#1 18.90
33,741.20
16.73
5,725
1.26
54.50
2,541.60
1,04,899.10
60.41
12,744.20
19.57
2,007
-10.91
52.39
980.10
98,621.00
21.20
23,511.00
13.82
4,615
-0.19
54.96
1,960.50
89,535.10
27.57
22,909.50
#1 19.94
3,306
#1 112.49
53.75
32,895.00
69,899.60
49.39
6,684.70
10.80
1,414
27.83
42.22
1,127.00
65,456.30
18.95
31,378.10
17.55
3,366
-0.50
47.15
Forecast
Actual
Growth Rate
Revenue Growth
457.18 %
Net Income Growth
289.29 %
Cash Flow Change
-1,739.81 %
ROE
-23.80 %
ROCE
-50.08 %
EBITDA Margin (Avg.)
-51.25 %

Quarterly Financial Results

Quarterly Financials
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Jun 2025
Revenue
80
104
80
92
108
117
134
Expenses
64
80
59
77
77
95
104
EBITDA
16
24
21
15
31
22
30
Operating Profit %
19 %
22 %
26 %
15 %
25 %
10 %
20 %
Depreciation
3
4
4
4
4
5
6
Interest
3
3
5
5
6
5
5
Profit Before Tax
10
18
14
16
21
21
27
Tax
3
3
3
3
4
3
5
Net Profit
7
14
11
13
16
18
21
EPS in ₹
4.01
8.03
3.39
2.78
5.04
3.81
4.60

Balance Sheet

Balance Sheet
2022
2023
2024
2025
Total Assets
59
131
622
1,227
Fixed Assets
7
27
235
435
Current Assets
27
51
251
722
Capital Work in Progress
8
35
97
44
Investments
15
17
0
57
Other Assets
29
53
289
0
Total Liabilities
59
131
622
1,227
Current Liabilities
10
52
248
241
Non Current Liabilities
13
34
143
174
Total Equity
37
46
232
786
Reserve & Surplus
28
36
174
740
Share Capital
9
10
31
46

Cash Flow

Cash Flow
2022
2023
2024
Net Cash Flow
2
-3
13
Investing Activities
-24
-48
-54
Operating Activities
-10
-1
-20
Financing Activities
37
46
87

Share Holding

% Holding
Jul 2024
Sept 2024
Dec 2024
Mar 2025
Jun 2025
Promoter
66.66 %
45.76 %
45.76 %
45.77 %
45.78 %
FIIs
0.00 %
5.51 %
4.25 %
4.17 %
3.67 %
DIIs
0.00 %
18.61 %
11.78 %
9.65 %
9.51 %
Government
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Public / Retail
0.00 %
27.88 %
28.71 %
31.43 %
31.44 %
Others
33.34 %
2.23 %
9.49 %
8.97 %
9.60 %
No of Share Holders
177
43,707
43,707
37,653
36,389

Corporate Action

Record Date Corporate Action Information Announcement Day LTP at Annoucement LTP at Record Day
23 Jul 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
23 Jul 2025 617.55 616.35
15 May 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
15 May 2025 483.75 541.05
23 Jan 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
23 Jan 2025 530.80 498.50

Announcements

Disclosure Under Regulation 30 Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 201516 hours ago
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome4 days ago
Announcement under Regulation 30 (LODR)-Newspaper Publication4 days ago
Announcement under Regulation 30 (LODR)-Investor Presentation5 days ago
Announcement under Regulation 30 (LODR)-Press Release / Media Release5 days ago
Announcement under Regulation 30 (LODR)-Monitoring Agency Report5 days ago
Announcement under Regulation 30 (LODR)-Change in Management5 days ago
Financial Results For Quarter Ended On June 30 20255 days ago
Board Meeting Outcome for Outcome Of The Board Meeting Held On July 23 20255 days ago
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation9 days ago
Board Meeting Intimation for Considering And Approving The Un-Audited Standalone And Consolidated Financial Results Of The Company For The Quarter Ended June 30 2025And To Transact Other Business MattersJul 17, 2025
Resubmission Of Intimation For Issuance Of The Corporate Guarantee Dated July 10 2025Jul 14, 2025
Announcement under Regulation 30 (LODR)-AcquisitionJul 10, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jul 10, 2025
Closure of Trading WindowJun 25, 2025
Update In Respect Of Our Earlier Intimations Dated March 11 2025 March 12 2025 And April 22 2025 Pursuant To Regulation 30 Of The SEBI (LODR) Regulations 2015Jun 23, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJun 18, 2025
Appointment Of Internal Auditors For FY 2025-26Jun 02, 2025
Board Meeting Outcome for Outcome Of Board Meeting Held On June 02 2025Jun 02, 2025
Compliances-Reg.24(A)-Annual Secretarial ComplianceMay 28, 2025
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011May 28, 2025
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptMay 22, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media Release (Revised)May 20, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMay 20, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeMay 16, 2025
Audited Standalone And Consolidated Financial Results For Quarter And Financial Year Ended March 31 2025May 16, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 16, 2025
Announcement under Regulation 30 (LODR)-Investor PresentationMay 16, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 16, 2025
Announcement under Regulation 30 (LODR)-Investor PresentationMay 16, 2025
Announcement under Regulation 30 (LODR)-Monitoring Agency ReportMay 15, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMay 15, 2025
Intimation Regarding Changes In The Senior Management Personnel (SMP) Of The CompanyMay 15, 2025
Appointment Of Secretarial Auditor For A Period Of Five (5) Consecutive Years From FY 2025-26 To FY 2029-30May 15, 2025
Board Meeting Outcome for Outcome Of Board Meeting Held On May 15 2025.May 15, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 12, 2025
Board Meeting Intimation for Considering And Approving The Audited Standalone And Consolidated Financial Results Of The Company For The Quarter And Financial Year Ended March 31 2025 And To Transact Other Business Matters.May 09, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media Release (Revised)May 09, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMay 05, 2025
Announcement Under Regulation 30 Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015May 02, 2025
Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure AApr 23, 2025
Update In Respect Of Our Intimations Dated March 11 2025 And March 12 2025 Pursuant To Regulation 30 Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015 (Listing Regulations)Apr 22, 2025
Intimation For Change In Contact Details Of MUFG Intime India Private Limited Registrar And Share Transfer Agent (RTA) Of The Company.Apr 19, 2025
Intimation For Change In Corporate Identity Number (CIN) And Listing Status Of Senores Pharmaceuticals Limited (Company) On The Ministry Of Corporate Affairs (MCA) Portal.Apr 04, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationApr 03, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Apr 03, 2025
Announcement Under Regulation 30 Of Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015- Issuance Of Corporate Guarantee.Apr 02, 2025
Closure of Trading WindowMar 27, 2025
Intimation Under Regulation 30(6) Of SEBI (LODR) Regulations 2015.Mar 20, 2025
Additional Disclosure In Respect Of Our Intimation Dated March 11 2025 Pursuant To Regulation 30 Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015 (Listing Regulations)Mar 12, 2025

Technical Indicators

RSI(14)
Neutral
62.35
ATR(14)
Volatile
28.36
STOCH(9,6)
Neutral
61.63
STOCH RSI(14)
Neutral
59.73
MACD(12,26)
Bullish
3.73
ADX(14)
Strong Trend
34.90
UO(9)
Bearish
49.49
ROC(12)
Uptrend But Slowing Down
9.56
WillR(14)
Neutral
-45.70

Mutual Fund Holdings